<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201214049723N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-01-07</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of 12-week Aerobic and Lower Extremity Resistance Exercises on Healing of Foot Ulcers in Type 2 Diabetic Patients</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of 12-week Aerobic and Lower Extremity Resistance Exercises on Healing of Foot Ulcers in Type 2 Diabetic Patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>26</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/53080</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Stratified block randomization using "dressing type" as matching factor between the groups. Online Randomization software will be used in randomization process. There will be 6 blocks, each containing 4 letters (e.g. AABB) as half of each block belongs to the control group and the other half belongs to the interventional group. These 6 blocks will be sorted out in a randomized fashion as well. The blocks will be placed in different sealed envelopes prepared by a third party that has no participation in any of the research stages whatsoever. Each time one of these envelopes will be unsealed randomly and 4 patients will be allocated according to the sequence of the letters inside that block. Then the envelope will be sealed and put in its position again, Blinding description: Outcome assessor will be blind to allocation before and after the intervention period.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Type 2 diabetic foot ulcer.</hc_freetext>
      <i_freetext>Intervention 1: Control group: Wound washing using saline and wound dressing change as standard care. Intervention 2: Intervention group: Wound washing using saline and wound dressing change as standard care + 12 weeks (3 sessions/week) of supervised aerobic and resistance exercise and home based range of motion exercise (3 days/week).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Iran University of Medical Sciences will decide whether to publish the data or not.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Ali Shakoorianfard</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 41, 5th alley, Najafzadeh Ave., Basij Blvd.</address>
        <city>Qom</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3715966345</zip>
        <telephone>+98 25 3783 1505</telephone>
        <email>mashakoorianfard1995@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Behnoosh Vasaghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Basic Sciences in Rehabilitation, School of Rehabilitation Sciences, Madadkaran alley, Shahnazari Ave., Madar Sq., Mirdamad St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1545913487</zip>
        <telephone>+98 21 2222 7124</telephone>
        <email>bvasaghi@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Type II DM according to ADA criteria for less than 20 years
Receiving medical care (diet, oral agents, insulin) throughout the disease course
Stable hypoglycemic medications (type &amp; dosage) within the last 2 months
Existence of at least one foot ulcer with Wound Surface Area ≤ 16 cm2
The ulcer must be classified as grade 2, stage A or C under the UTCS
Stable anti inflammatory drugs (drugs prescribed to control HTN or hyperlipidemia) during the last 3 months
At least 18 years of age
BMI &lt; 35
0.7 ≤ ABI ≤ 1.4
6.5% ≤ HbA1C ≤ 9.5%
100 ≤ FBS ≤ 250 mg/dl
Sedentary lifestyle for the last 6 months</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Cognitive or mental deficit
Wound treatments other than standard care (deemed to be required by the physician) such as growth factors, NPWT, hyperbaric oxygen, special dressings, etc.
Ulcer requiring surgical operations other than debridement
Non-diabetic ulcers such as electrical, chemical or radiation burns, etc.
Pregnancy or breast feeding
Infection or OM
Critical limb ischemia or lower extremity gangrene
Proliferative retinopathy or history of retinal detachment
Moderate or severe kidney disease
History of major lower extremity amputation
Severe liver disease
Uncontrolled HTN or BP higher than 160/95 mmHg
Life-threatening disease such as malignancy
History of DVT during the last 6 months
Active cellulitis or collagen vascular disease
Active Charcot
Present history of smoking or alcoholism
Dialysis
Immunodeficiency caused by immunosuppressant usage or chemotherapy during the past 2 months, radiotherapy within the last 4 months or systemic diseases
Presence of any overt cardiovascular condition diagnosed by cardiologist that prevents the patient from performing vigorous activities
Any kind of disease or condition (orthopedic, neurologic, pulmonary, arthritis, etc.) that limits or contraindicates physical activity
Presence of any condition considered as absolute contraindication for physical activity by the ACSM’s guideline
Participating in any experimental or non-experimental program that requires regular physical activity</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E11.621</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Type 2 diabetes mellitus with foot ulcer</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: Wound washing using saline and wound dressing change as standard care</i_keyword>
      <i_keyword>Intervention group: Wound washing using saline and wound dressing change as standard care + 12 weeks (3 sessions/week) of supervised aerobic and resistance exercise and home based range of motion exercise (3 days/week)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Wound surface area. Timepoint: Baseline, at the end of 4th, 8th and 12th weeks. Method of measurement: Taking pictures and using the "NIH Imagej" software for wound surface area measurement.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Quality of life. Timepoint: Baseline and the end of 12th week. Method of measurement: Iranian version of The Short Form 36 Health Survey (SF-36).</sec_outcome>
      <sec_outcome>Ankle Brachial Index (ABI). Timepoint: Baseline, at the end of 4th, 8th and 12th weeks. Method of measurement: Ankle Brachial Index measurement device which measures systolic blood pressure at arm and ankle levels and calculates the exact value.</sec_outcome>
      <sec_outcome>5 blood parameters (Interleukin-6, Interleukin-10, Insulin-like Growth Factor-1, Tumor Necrosis Factor-α and Vascular Endothelial Growth Factor). Timepoint: Baseline and at the end of 12th week. Method of measurement: Taking blood samples and using special laboratory kits.</sec_outcome>
      <sec_outcome>Wound depth. Timepoint: Baseline, at the end of 4th, 8th and 12th weeks. Method of measurement: Using wound depth measurement sterile probe and disposable paper ruler.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-12-06</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Hemmat Hwy. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
